Immune Response News and Research

RSS

Study sheds light on why lung tumors do not respond well to immunotherapy

Immunotherapy -; drug treatment that stimulates the immune system to attack tumors -; works well against some types of cancer, but it has shown mixed success against lung cancer.

6 Feb 2023

Losartan prevents immunotherapy-related edema, improves survival in glioblastoma mouse models

Patients with glioblastoma-;the deadliest type of primary brain tumor-;may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.

3 Feb 2023

Scientists develop new design principles to improve cancer vaccines

A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.

1 Feb 2023

Study findings may pave way for personalized cancer treatment

In a step likely to advance personalized cancer treatment, scientists have for the first time shown in patients that levels of biomarkers are not enough to tell which patients are likely to respond best to immunotherapy.

31 Jan 2023

Massive clinical study on type 1 diabetes patients

A massive clinical study on an approved psoriasis drug is now underway. The drug will be tested on people who have just been diagnosed with type 1 diabetes. The drug, according to the theory, could preserve the patient’s remaining insulin production.

30 Jan 2023

Long-term deep meditation may have a beneficial effect on gut microbiota, study suggests

Regular deep meditation, practised for several years, may help to regulate the gut microbiome and potentially lower the risks of physical and mental ill health, finds a small comparative study published in the open access journal General Psychiatry.

30 Jan 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Analysis of pancreatic cancer's microenvironment reveals cause of tumor cell resistance to immunotherapy

A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.

27 Jan 2023

Persistent tumor mutation load may help predict outcome of novel immunotherapies

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

27 Jan 2023

Figuring out how cells safeguard their genomes during replication

Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome, a cell’s complete set of DNA, is most vulnerable while it is being duplicated before a cell divides.

26 Jan 2023

New revelations on the immune system’s defenses against infections

Cells competing for a place in a germinal center confront a tough admissions process. Germinal centers, which form following exposure to a pathogen or vaccine, serve as a kind of immune system training academy, assisting B cells in refining their response to the threat.

18 Jan 2023

Detecting the extent of natural selection over time

Institut Pasteur, Université Paris Cité, the CNRS, and the Collège de France researchers have employed paleogenomics to trace 10,000 years of human immune system evolution. They examined the genomes of over 2,800 individuals who lived in Europe over the past 10 millennia.

From Institut Pasteur 18 Jan 2023

Innovative approach to mRNA delivery

A group of scientists spearheaded by The University of Texas MD Anderson Cancer Center has created a unique messenger RNA (mRNA) delivery system utilizing extracellular vesicles (EVs).

16 Jan 2023

A new-found possibility for viral and cancer drug therapies

Researchers have found that sugar-based molecules can be used to inhibit the activity of a cell receptor that plays a role in the emergence of a variety of viral infections and cancers.

13 Jan 2023

New solution to treat diseases caused by exaggerated inflammation

A recent study guided by the Instituto Gulbenkian de Ciência (IGC) shows how anticancer drugs reduce inflammation, establishing them as prospective sepsis treatments.

11 Jan 2023

Researchers expand the known defensive abilities of CRISPR–Cas systems

Viruses can infect bacteria and archaea, just as they can humans. These microbes have evolved their own immune defense mechanisms to combat their pathogens. Bacterial defenses, like CRISPR-Cas systems, contain a variety of proteins and functions that aid bacteria in protecting themselves from foreign intruders.

5 Jan 2023

New technologies reveal cross-cutting breakdowns in Alzheimer’s disease

A figure from the paper depicts pathways perturbed in Alzheimer's disease. Below examples are listed for each pathway by major brain cell type. Image Credit: The Picower Institute.

4 Jan 2023

Key immune alarm protein that regulates inflammation identified

Trinity researchers have made a significant advance in understanding how inflammation is controlled. They recently discovered that a crucial immunological alarm protein that was previously thought to quiet the immune response apparently performs the opposite.

20 Dec 2022

Improving cancer immunotherapies with bioengineered synthetic gene circuits

In two distinct studies, scientists show how synthetic biology can be used to address a challenging problem in cancer immunotherapy: the way immunotherapy-related approaches focused on the short-term killing of tumor cells could fail to eradicate tumors because tumor growth occurs on longer timescales.

19 Dec 2022

Predictive classifier identifies patients who can skip radiation therapy

According to the findings of a meta-analysis proposed at the San Antonio Breast Cancer Symposium held on December 6–10th, 2022, patients with invasive breast cancer who had low scores on an investigational gene molecular signature seemed to have similar rates of local recurrence regardless of whether they received adjuvant radiation therapy after breast-conserving surgery.

12 Dec 2022